Characterizing Spondyloarthritis With 68Ga-FAPI PET/CT

Status Recruiting

Clinical Trial Summary

To evaluate the potential usefulness of 68Ga-FAPI PET/CT for the diagnosis, inflammation evaluation and prognosis prediction in spondyloarthritis.

Clinical Trial Description

Spondyloarthritis (SpA) is a chronic inflammatory rheumatic disease characterized by inflammatory back pain, enthesitis, dactylitis, and the formation of syndesmophytes, all of which significantly affect a patient's healthy functioning and general quality of life. Prevalence of underlying malignancy is high in patients with SpA. Radiographic sacroiliitis became a crucial finding in the diagnosis and classification of patients. 68Ga-FAPI has been developed as tracers specific for fibroblast-activation protein (FAP), which is overexpressed in activated fibroblasts in various type of cancers and autoimmune diseases, such as rheumatoid arthritis, IgG4-related diseases and interstitial lung diseases. Recently the investigators have published articles of the application of 68Ga-FAPI in IgG4-related disease and rheumatoid arthritis, which showed it was more sensitive than FDG in detecting a certain type of inflammation. Increased 68Ga-FAPI Uptake in ankylosing spondylitis in a patient with rectal cancer has also been reported in a case report, indicating the potential utility of FAP-targeted PET/CT imaging for diagnosis and disease assessment in spondyloarthritis. Thus, this prospective study is going to investigate utility of 68Ga-FAPI PET/CT in diagnosis of spondyloarthritis as well as inflammation assessment in joints including the sacroiliac (SI) joints, spine and peripheral joints. Also, this study aims to investigate potential utility of 68Ga-FAPI PET/CT in predicting treatment response and disease prognosis such as formation of syndesmophytes and erosive changes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05999643
Study type	Interventional
Source	The First Affiliated Hospital of Xiamen University
Contact	Yuan Liu, MD
Phone	86 0592-2137749
Email	iuyuan@xmu.edu.cn
Status	Recruiting
Phase	N/A
Start date	July 1, 2023
Completion date	August 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02685904` - A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis	Phase 3
Completed	`NCT02186873` - A Study of Golimumab in Participants With Active Ankylosing Spondylitis	Phase 3
Completed	`NCT01668004` - The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)	Phase 4
Completed	`NCT05051943` - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed	`NCT01934933` - Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis	Phase 4
Not yet recruiting	`NCT04875299` - Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
Completed	`NCT02758782` - NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis	Phase 4
Completed	`NCT02763111` - Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis	Phase 2
Active, not recruiting	`NCT02687620` - Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
Completed	`NCT02154425` - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers	Phase 1
Completed	`NCT01750528` - Prevalence and Progression of Periodontitis in Ankylosing Spondylitis	N/A
Completed	`NCT01463189` - Web-based Support to Manage Arthritis Pain	Phase 2
Completed	`NCT01091675` - Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs	Phase 3
Completed	`NCT00844805` - Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)	Phase 3
Recruiting	`NCT00747578` - Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan	N/A
Completed	`NCT01083693` - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs	N/A
Completed	`NCT00715091` - Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis	Phase 4
Not yet recruiting	`NCT00517101` - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy	N/A
Completed	`NCT00367211` - Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.	Phase 3
Completed	`NCT00133315` - TNFalfa Blocking Treatment of Spondylarthropathies	Phase 4